Groupe Hospitalier Nord Essonne
- Address
- 4 Place Du General Leclerc, 91400 Orsay, France
Groupe Hospitalier Nord Essonne - Multidisciplinary Clinical Research Center
Groupe Hospitalier Nord Essonne is a comprehensive clinical research institution conducting innovative trials across multiple therapeutic areas. The center demonstrates particular expertise in critical care medicine, oncology, neuroscience, and infectious diseases, with a strong focus on developing personalized treatment approaches and optimizing antibiotic stewardship.
- Critical Care and Intensive Care Medicine: investigating novel treatments for septic shock, ventilator-associated pneumonia, and severe electrolyte disturbances
- Gastrointestinal Oncology: advancing targeted therapies for colorectal cancer and metastatic oeso-gastric adenocarcinoma with focus on KRAS mutations and combination treatment strategies
- Neuropsychiatry and Neuroscience: studying early psychosis intervention, multiple sclerosis remyelination, and primary CNS lymphoma imaging with innovative PET-MR techniques
- Antimicrobial Optimization: evaluating shortened antibiotic regimens for pediatric pyelonephritis and complicated appendicitis to reduce treatment burden
The center's research portfolio reflects a commitment to precision medicine and evidence-based treatment optimization. Notable studies include investigating composite personalized care for early psychosis patients, evaluating DDAVP for preventing sodium overcorrection in severe hyponatremia, and pioneering the use of levetiracetam for delirium prevention in septic shock. The institution's work in advanced imaging modalities, particularly PET-MR technology, positions it at the forefront of diagnostic innovation for neurological conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 55 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Groupe Hospitalier Nord Essonne
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study | Novartis Pharma AG | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 55 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 3 | Unknown | 2024-02-09 | 2025-08-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.